MedTrace Logo

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

NCT03492697 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-07-30

No results posted yet for this study

Summary

This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

PF-06882961 Immediate Release Tablet

Immediate Release Tablet

DRUG

PF-06882961 Controlled Release Tablet (long)

Controlled Release tablet (long)

DRUG

PF-06882961 Controlled Release Tablet (short)

Controlled Release tablet (short)

DRUG

PF-06882961 Immediate Release Solution

PF-06882961 Immediate Release solution

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2018-07-18
Completion
2018-07-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03492697 on ClinicalTrials.gov